Oxurion NV (0G99.L)

0.0001 0.0000 (0.00%) As of 08:23AM BST. Market open.

Oxurion NV

Gaston Geenslaan 1
Leuven 3001
Belgium
32 1 675 13 10
https://www.oxurion.com

Sector(s): 
Industry: 
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Ghoson	CEO, CFO & Executive Director	N/A	N/A	N/A
Philippe Barbeaux Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Andy De Deene M.B.A., M.D.	Chief Development Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Corporate governance

Oxurion NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.